Neurofibromin 1 Antikörper (AA 160-270)
Kurzübersicht für Neurofibromin 1 Antikörper (AA 160-270) (ABIN7600195)
Target
Alle Neurofibromin 1 (NF1) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Bindungsspezifität
- AA 160-270
- 
                                            Verwendungszweck
- Anti-Neurofibromin/NF1 Antibody Picoband®
- 
                                            Kreuzreaktivität (Details)
- No cross-reactivity with other proteins.
- 
                                            Produktmerkmale
- Anti-Neurofibromin/NF1 Antibody Picoband® (ABIN7600195). Tested in ELISA, Flow Cytometry, IF, IHC, ICC, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
- 
                                            Aufreinigung
- Immunogen affinity purified.
- 
                                            Immunogen
- E.coli-derived human Neurofibromin/NF1 recombinant protein (Position: R160-Q270).
- 
                                            Isotyp
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- 
                        Western blot, 0.25-0.5 μg/mL, Human
 Immunohistochemistry (Paraffin-embedded Section), 2-5 μg/mL, Human
 Immunocytochemistry/Immunofluorescence, 2 μg/mL, Human
 Flow Cytometry (Fixed), 1-3 μg/1x106 cells, Human
 ELISA, 0.1-0.5 μg/mL, -
 1. Scheffzek K, Welti S (2012). "Neurofibromin: Protein Domains and Functional Characteristics". In Upadhyaya M, Cooper D (eds.). Neurofibromatosis Type 1. Berlin, Heidelberg: Springer. pp. 305-326. 2. Trovó-Marqui AB, Tajara EH (July 2006). "Neurofibromin: a general outlook". Clinical Genetics. 70 (1): 1-13. 3. Peltonen S, Pöyhönen M (2012). "Clinical Diagnosis and Atypical Forms of NF1". In Upadhyaya M, Cooper D (eds.). Neurofibromatosis Type 1. Berlin, Heidelberg: Springer. pp. 17-30.
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Lyophilized
- 
                                            Rekonstitution
- Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
- 
                                            Konzentration
- 500 μg/mL
- 
                                            Buffer
- Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.
- 
                                            Konservierungsmittel
- Sodium azide
- 
                                            Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            Lagerung
- 4 °C,-20 °C
- 
                                            Informationen zur Lagerung
- 
                        Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. 
 It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.
 
- 
                                            
- 
    - Neurofibromin 1 (NF1)
- 
                                            Andere Bezeichnung
- NF1
- 
                                            Hintergrund
- 
                        Synonyms: Neurofibromin, Neurofibromatosis-related protein NF-1, Neurofibromin truncated, NF1 Tissue Specificity: Detected in brain, peripheral nerve, lung, colon and muscle. Background: Neurofibromin 1 (NF1) is a gene in humans that is located on chromosome 17. This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. 
- 
                                            Molekulargewicht
- 319 kDa
- 
                                            Gen-ID
- 4763
- 
                                            UniProt
- P21359
- 
                                            Pathways
- cAMP Metabolic Process, Regulation of long-term Neuronal Synaptic Plasticity
 Target
- 
                    
 
                                     
                                     
                                    